Abstract

Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance

Author(s): Pellagatti Tommaso, Ternelli Marco, Frascio Davide, Bettini Ruggero

Issue: May/Jun 2017 - Volume 21, Number 3

Page(s): 247-250

Download in electronic PDF format for $75
  • Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance Page 1
  • Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance Page 2
  • Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance Page 3
  • Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance Page 4

Abstract

Warfarin is still the most prescribed oral anticoagulant prescribed for the prophylaxis and treatment of thromboembolic events such as stroke, heart attack, embolism, and deep vein thrombosis. It is administered orally in the form of sodium salt as a tablet with a typical strength of 5 mg. The molecule has a narrow therapeutic index. As a consequence, the dosage must be individualized for each patient based on the patient response in terms of time of coagulation. Thus, warfarin represents an example of a drug whose dose needs to be tailored to individual requirements that are often changing and, therefore, constitute a paramount illustration of personalized medicine. The aim of the present work was to investigate to what extent the manual division of a warfarin tablet by the patient represents an issue in terms of dose accuracy and precision. A second goal was to demonstrate that possible problems stemming from the manual division of the warfarin tablet could be overcome by compounding a solid dosage form (e.g., a capsule) starting from the commercially available warfarin product. The results of the present study put into evidence the great inhomogeneity and discrepancy from the target dose obtained when commercially available warfarin tablets are manually divided in four parts. This represents a potential source of inefficacy of the anticoagulant activity, with increased risk of either bleeding or thromboembolic events. The proposed solution is effective and yet simple and economically affordable, in particular considering the cost of the possible hospitalizations related to therapy failure.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2017
Pg. 247-250
Mar/Apr 2018
Pg. 108-121
Mar/Apr 2022
Pg. 163-174
Nov/Dec 2023
Pg. 468-473
Nov/Dec 2017
Pg. 468
Author(s): Blankenship Cynthia
Sep/Oct 1997
Pg. 356-358
Jul/Aug 2016
Pg. 351
View Sample
Author(s): Allen Loyd V Jr
Nov/Dec 2020
Pg. 451-458
Mar/Apr 2016
Pg. 155-158
Sep/Oct 2017
Pg. 356
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 379-380
Jan/Feb 2014
Pg. 6-12
Jul/Aug 2018
Pg. 268
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 169-175
Jul/Aug 2015
Pg. 307-310
Author(s): Sidhu Raman
Jul/Aug 2015
Pg. 280-287
Author(s): Allen Loyd V
Jan/Feb 2023
Pg. 24-29
Author(s): Rachmawati Putriana
Sep/Oct 2014
Pg. 358-364
Mar/Apr 2018
Pg. 95-107
Jan/Feb 2020
Pg. 30-36
Author(s): Dillon L R